ICH’s GCP Guideline

Table of Contents

Last Updated: March 12th, 2026

Introduction

The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) is a collaboration of regulatory authorities and industry experts from Europe, Japan, the United States, and other regions around the world. The goal of the collaboration is to harmonize scientific and technical requirements so that they can be applied internationally, reducing the need for duplicate testing and streamlining the drug development process.

One of the most important guidelines that ICH has published is the Guideline for Good Clinical Practice (GCP), known as ICH E6. This document describes the responsibilities and expectations of all participants in the conduct of clinical trials, including investigators, monitors, sponsors, and IRBs/ethics committees. GCP covers aspects of trial design, conduct, monitoring, recording, reporting, and archiving.

The ICH GCP guideline has gone through three versions:

E6(R1): the original guideline, published in May 1996. This established the foundational international standard for clinical trial conduct.
E6(R2): an integrated addendum adopted in 2016. It introduced concepts such as risk-based monitoring and the use of electronic records, while preserving the original structure.
E6(R3): the current version, adopted by the ICH Assembly on January 6, 2025. This is a comprehensive restructuring of the entire guideline, reflecting how clinical trials are designed and conducted today – including decentralized trials, quality management systems, and technology-enabled oversight.

“Good Clinical Practice (GCP) is an international, ethical, scientific and quality standard for the conduct of trials that involve human participants. Clinical trials conducted in accordance with this standard will help to assure that the rights, safety and well-being of trial participants are protected; that the conduct is consistent with the principles that have their origin in the Declaration of Helsinki; and that the clinical trial results are reliable.”
– ICH Guideline for Good Clinical Practice E6(R3)

ICH GCP E6(R3): The Current Guideline

Since its original publication in 1996, the ICH GCP guideline has undergone two major revisions:

E6(R2) was adopted in 2016 as an integrated addendum to the original E6(R1). It introduced concepts such as risk-based monitoring and electronic records but largely preserved the original structure and content.
E6(R3) was adopted by the ICH Assembly on January 6, 2025. This is not simply another addendum – it is a comprehensive restructuring of the entire guideline to reflect how clinical trials are designed and conducted today.

What Changed in E6(R3)

E6(R3) introduces several significant changes from E6(R2):

New structure
The guideline is now organized into an overarching Principles document, Annex 1 (covering interventional clinical trials), and Annex 2 (covering non-traditional interventional trials such as pragmatic, decentralized, and registry-based trials). Annex 2 was still being finalized as of mid-2025.
Quality Management Systems (QMS)
E6(R3) places much greater emphasis on sponsors and sites implementing quality management systems to proactively identify and manage risks to trial quality, rather than relying solely on after-the-fact monitoring.
Quality by Design
The guideline introduces a “fit for purpose” approach, encouraging sponsors to design quality into the trial from the start – identifying what is critical to participant safety and data reliability, and focusing resources accordingly.
Risk-proportionate monitoring
While E6(R2) introduced the concept of risk-based monitoring, E6(R3) goes further by embedding proportionate oversight as a core principle. Rather than performing 100% source data verification on every data point, CRAs and sponsors are expected to focus monitoring efforts on critical data and processes.
Decentralized clinical trials (DCTs)
E6(R3) formally recognizes the growing use of decentralized and hybrid trial designs, where some or all trial activities occur outside the traditional clinical site. This includes guidance on remote monitoring, telehealth visits, electronic consent (eConsent), and the use of digital health technologies.
Participant-centered approach
The guideline places increased focus on considering the participant perspective in trial design and conduct, including how information is communicated to participants and how consent is obtained.
Media-neutral approach
E6(R3) adopts a “media neutral” stance – meaning its principles apply regardless of whether records are maintained on paper, electronically, or through other media. This replaces the more paper-centric assumptions in earlier versions.
Informed consent enhancements
More detailed guidance is provided on obtaining informed consent, including the use of technology to inform participants and obtain their consent electronically.

E6(R3) Adoption Timeline

The adoption of E6(R3) is happening on a region-by-region basis:

European Union
The European Medicines Agency (EMA) announced that E6(R2) remained in effect until June 11, 2025. The E6(R3) Principles and Annex 1 became effective on June 12, 2025, and entered legal effect in the EU on July 23, 2025.
United States
The FDA published a Federal Register notice on E6(R3) in September 2025. As of this writing, formal FDA adoption is still pending. In the interim, E6(R2) remains the FDA’s stated standard, though E6(R3) principles are increasingly being applied in practice.
Other regions
Other ICH member regions (including Japan, Canada, and others) are implementing E6(R3) according to their own regulatory timelines.

What This Means for CRAs and Clinical Research Professionals

If you work in clinical research, E6(R3) affects you directly. For CRAs, the shift toward risk-proportionate monitoring, quality management systems, and technology-enabled oversight means the skills required for the role are evolving. Familiarity with E6(R3) is becoming essential – not optional.

Both ACRP and SOCRA have updated their certification exam content to reflect E6(R3). SOCRA’s CCRP exam has been based on E6(R3) since January 1, 2026, and ACRP will begin incorporating E6(R3) into its certification exams starting with the Fall 2026 testing window. If you are studying for either certification exam, make sure your study materials are current. Visit our CCRP Certification: ACRP vs. SOCRA page for more details.

For a deeper look at how these changes are shaping day-to-day CRA work — including hybrid monitoring, decentralized trials, and the growing importance of data analytics — visit our CRA Career Progression & Levels page.

How ICH’s GCP is Used

In the United States

The ICH GCP guideline is endorsed by the FDA in the United States. It should be used in addition to the human subjects protections regulations (45 CFR 46) and FDA Code of Federal Regulations (CFR). When there are differences between the ICH guideline and FDA regulations, the FDA CFR takes precedence as the standard of practice.

As of this writing, the FDA has not yet formally adopted E6(R3). The FDA published a Federal Register notice on the availability of the E6(R3) guideline in September 2025, signaling its intent to transition, but formal implementation is still pending. In the interim, E6(R2) remains the FDA’s stated reference.

However, many sponsors and CROs operating in the United States are already aligning their practices with E6(R3) principles, particularly around quality management systems, risk-proportionate monitoring, and decentralized trial conduct, since trials conducted globally need to meet the standards of all applicable regulatory authorities.

In the European Union

The European Medicines Agency (EMA) has fully adopted E6(R3). The E6(R3) Principles and Annex 1 became effective on June 12, 2025, and entered legal effect in the EU on July 23, 2025. E6(R2) is no longer in effect in the EU. Any clinical trial being conducted in an EU member state is now expected to comply with E6(R3).

In the Rest of the World

ICH’s GCP guideline has long provided a unified standard across ICH member regions, including the European Union, Japan, the United States, Canada, Australia, and others. Many non-ICH countries including those in Latin America, Asia, and Africa also adopt or reference ICH GCP in their own national regulations.

With the release of E6(R3), each region is implementing the updated guideline according to its own regulatory timeline. For sponsors and CROs running multinational or global clinical trials, this means there may be a transitional period where some regions are operating under E6(R3) and others are still referencing E6(R2). In practice, sponsors conducting global trials are encouraged to align with E6(R3) as the most current standard, while also ensuring compliance with any applicable local regulations.

Investigator’s Responsibilities from ICH’s GCP

Investigator’s Responsibilities is an important section of the ICH’s GCP. As part of investigator’s qualification, I usually go over this section with the site investigator to ensure that they understand their role and responsibilities. Below are some of the responsibilities for an investigator:

Have appropriate qualifications and resources
Provide adequate medical care for any adverse experiences
Provide IRB with appropriate documents and obtain IRB approval
Comply with the protocol, deviating only with IRB approval, except in case of emergency
Follow randomization and blinding procedures
Obtain and document informed consent
Inform subjects, IRB, sponsor, and the institution of premature termination
Ensure the appropriate use of the investigational product at the trial site
Proper handling, storage and recordkeeping of the investigational product at the clinical site
Keep case report forms (CRFs) and allowing access to the IRB, monitors, auditors, and the FDA
Maintain appropriate trial related documents
Document financial arrangements with the sponsor
Provide progress reports to the IRB at least annually
Report significant changes to the sponsor and IRB
Report adverse experiences to the sponsor and IRB
Produce final reports
Retain the records and reports for 2 years after a marketing application is approved; or, if an application is not approved for the drug, until 2 years after shipment and delivery of the drug for investigational use is discontinued and the FDA has been notified

Clinical Trial Monitoring Under ICH’s GCP

ICH’s GCP describes clinical trial monitoring as one of the important responsibilities of the sponsor. The core purpose of monitoring has remained consistent across all versions of the guideline – to ensure that:

The rights and well-being of human subjects are protected
The reported data are accurate, complete and verifiable
The conduct of the trial complies with the protocol, GCP, and applicable regulations

Identification, correction, and prevention of problems in the above areas are part of the work required as CRAs conduct monitoring visits.

How Monitoring Has Evolved Under E6(R3)

While the purpose of monitoring has not changed, the approach to monitoring has evolved significantly – particularly with the adoption of E6(R3).

Under E6(R2), the concept of risk-based monitoring was introduced, encouraging sponsors to develop a systematic approach to monitoring rather than relying solely on routine on-site visits with 100% source data verification (SDV). E6(R3) takes this further by embedding risk-proportionate oversight as a core principle of the guideline.

In practice, this means:

Focus on what matters most
Rather than verifying every data point at every site, sponsors and CRAs are expected to identify what is critical to participant safety and data reliability and focus monitoring resources there. Not all data carries the same level of risk, and monitoring plans should reflect that.
Centralized monitoring
E6(R3) supports the use of centralized monitoring techniques, where data is reviewed remotely using statistical and analytical methods to detect trends, outliers, and potential issues across sites. This complements (but does not replace) on-site monitoring.
Risk indicators and escalation
CRAs are increasingly expected to work with Key Risk Indicators (KRIs) and centralized monitoring dashboards to identify sites or data areas that need closer attention. Knowing when and how to escalate findings is a critical skill in this model.
On-site visits remain important
Risk-based monitoring does not mean fewer site visits across the board. It means that the frequency, scope, and focus of visits should be driven by the risk profile of the study and the individual site with more attention directed where it is needed most.
Quality Management Systems (QMS)
E6(R3) expects sponsors to have a quality management system in place that supports ongoing identification and management of risks throughout the trial, not just during monitoring visits.

For CRAs, this shift means that data literacy, analytical thinking, and the ability to interpret risk signals are becoming just as important as traditional source data verification skills. CRAs who can combine strong on-site monitoring fundamentals with centralized data review capabilities will be well-positioned in the evolving clinical research landscape.